疾病
医学
重症监护医学
临床试验
细胞
儿科
内科学
生物
遗传学
作者
Carolyn Hoppe,Lynne Neumayr
标识
DOI:10.1016/j.hoc.2019.01.014
摘要
Screening and early detection of organ injury, as well as expanded use of red cell transfusion and hydroxyurea in children have changed best practices for clinical care in sickle cell disease . The current standard of care for children with sickle cell disease is discussed through a review of screening recommendations, disease monitoring, and approach to treatment. Novel pharmacologic agents under investigation in clinical trials are also reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI